LT
About
Lysosomal Therapeutics is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Their strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies.
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 491 investors are based in Cambridge, Massachusetts, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- Cambridge, US
Contact Information
linkedin.com/in/••••••••
Find more investors like Lysosomal
Search Investors